2011 |
Dr. Kirsten Jacobs |
Regulatory Requirements for medical devices in major countries of Latin America |
|
|
2011 |
Christophe Klumb |
Making cellular therapies available to patients - Possible regulatory pathways in Europe and Germany *** |
|
|
2011 |
Stefanie Lauhoff |
Die Überarbeitung der Packungsgrößenverordnung im Rahmen des AMNOG und deren praktische Auswirkungen *** |
|
|
2011 |
Dr. Stefan Leyers |
'Chemo-similars', a new challenge for regulatory affairs?! |
|
|
2011 |
Daniela Meinl |
DCP Slot Allocation within European Health Authorities and its impact on Development and Regulatory Strategies of Generic Companies Summary |
|
|
2011 |
Natascha Nickelt |
Regulatory Assessment of Nanotechnology in Different Areas of Application -an Example of Regulating Emerging Sciences *** |
|
|
2011 |
Dr. Gabriele Noffz |
Novel biomedical products: Conventional biologicals or ATMPs *** |
|
|
2011 |
Dr. Petra Regenhard |
Regulatory Requirements in the European Union for Avian Vaccines: Impact of the "Guideline on Data Requirements for Immunological Veterinary Medicinal Products intended for Minor Use or Minor Species/Limited Markets" on Clinical Research |
|
|
2011 |
Dr. Saskia Siewert |
Implementation of Quality by Design in the Pharmaceutical Development of semisolid topical drug products *** |
|
|
2011 |
Dr. Liane Söllner |
The need for juvenile animal studies - a critical review *** |
|
|
2011 |
Sebastian Strobl |
Counterfeit drugs in industrialized and developing countries - A comparison *** |
|
|
2011 |
Dr. Verena Tautorat |
The end of an era: Implementing Variation Directive 2009/53/EC into German Drug Law *** |
|
|
2011 |
Dr. Franz Thannberger |
A Step beyond Module 3 of "passive" Transdermal Therapeutic Systems *** |
|
|
2011 |
Anja Then-Kania |
Postapproval CMC Changes in the United States with a Focus on Biopharmaceuticals - Current Status and an Outlook in the Pharmaceutical Development *** |
|
|
2011 |
Kristina Tripp |
Case Study: Impact of a new German law ("AMNOG") to restructure the pharmaceutical market on a Generic Company |
|
|
2011 |
Dr. Alexander Vuia |
First revision of the "Guideline on the Investigation of bioequivalence": BCS-based Biowaiver - opportunities and limitations |
|
|
2011 |
Dr. Bettina Walter-Lorenzen |
Improvement of the workflow, quality and effective management of product information texts using a new database |
|
|
2011 |
Katrin Wengenroth |
Regulatory Challenges Due to Globalisation of Drug Development and Manufacture Focusing on the Quality of Medicinal Products *** |
|
|
2010 |
Sigrun Adrian |
Die Entwicklung unterschiedlicher Rechtsvorschriften und deren Überwachung im Bereich der Sicherheit von Arzneimitteln und Medizinprodukten in Deutschland (Pharmako- und Medizinproduktevigilanz) |
|
|
2010 |
Stanislaus Awrutski |
Drug Regulatory Affairs and Marketing Authorisation in the Post-Soviet countries. Focus: Russia, the Ukraine and Belarus |
|
|